The Company issued the following warrants to purchase shares of its common stock, which are outstanding as of June 30, 2026 and December 31, 2025, respectively. These warrants are exercisable any time at the option of the holder until their expiration date.


	Issuance Date	Term	Exercise Price Per Share		Outstanding at December 31, 2025		Issued during the Six Months Ended June 30, 2026		Exercised during the Six Months Ended June 30, 2026			Expired during the Six Months Ended June 30, 2026			Outstanding at June 30, 2026
June 2026 Pre-Funded Warrants	June 2026	perpetual	$	—		—		3,883,496		—			—			3,883,496
December 2022 Service and Performance Warrants (1)	December 2022	5 years	$	11.20		1,000		—		—			—			1,000
October 2022 Service and Performance Warrants (1)	October 2022	5 years	$	16.00		1,000		—		—			—			1,000
January 2021 Placement Agent Warrants	January 2021	5.5 years	$	159.60		9,846		—		—			—			9,846
December 2020 Warrants (2)	December 2020	5.5 years	$	9.00		16,367		—		(16,367	)		—			—
December 2020 Warrants	December 2020	5.5 years	$	120.00		49,100		—		—			(49,100	)		—
July 2020 Warrants (2)	July 2020	5.5 years	$	9.00		16,036		—		—			(16,036	)		—
July 2020 Placement Agent Warrants	July 2020	5.5 years	$	198.80		802		—		—			(802	)		—
January 2021 Warrants (2)	January 2021	5.5 years	$	9.00		7,831		—		(7,831	)		—			—
January 2021 Warrants	January 2021	5.5 years	$	125.20		90,629		—		—			—			90,629
Total						192,611		3,883,496		(24,198	)		(65,938	)		3,985,971

(1) The Company issued service and performance warrants (“Service and Performance Warrants”) in connection with professional services agreements with non-affiliated third party entities.

(2) These warrants were repriced as part of the March 2023 Private Placement.

The preferred investment options issued in connection with the June 2026 Private Placement, January 2026 Inducement Offer, March 2023 Private Placement and August 2022 Registered Direct Offering contain certain early settlement provisions that preclude them from equity classification and therefore were accounted for as liabilities at the date of issuance and are adjusted to fair value at each balance sheet date. The change in fair value of the options liabilities is recorded as change in fair value of common stock warrant and option liabilities in the condensed consolidated statements of operations and comprehensive loss. The key terms and activity of the liability classified preferred investment options are summarized as follows:


	Issuance Date	Term	Exercise Price Per Share		Outstanding at December 31, 2025		Issued during the Six Months Ended June 30, 2026		Exercised during the Six Months Ended June 30, 2026			Expired during the Six Months Ended June 30, 2026		Outstanding at June 30, 2026
June 2026 Options - Series A-1	June 2026	5 years	$	0.91		—		3,883,496		—			—		3,883,496
June 2026 Options - Series A-2	June 2026	2 years	$	0.91		—		3,883,496		—			—		3,883,496
June 2026 Placement Agent Options	June 2026	5 years	$	1.29		—		271,845		—			—		271,845
January 2026 Options	January 2026	2.5 years	$	2.33		—		1,617,190		—			—		1,617,190
January 2026 Placement Agent Options	January 2026	2.5 years	$	3.22		—		56,602		—			—		56,602
March 2023 Options - Series A	March 2023	5 years	$	9.00		666,334		—		(666,334	)		—		—
March 2023 Placement Agent Options	March 2023	5 years	$	11.25		33,317		—		—			—		33,317
August 2022 Options (1)	August 2022	5 years	$	9.00		118,063		—		(118,063	)		—		—
August 2022 Placement Agent Options	August 2022	5 years	$	52.80		5,904		—		—			—		5,904
Total						823,618		9,712,629		(784,397	)		—		9,751,850

(1) These options were repriced as part of the March 2023 Private Placement.